Pfizer Inc (PFE.N) and BioNTech SE (22UAy.F) said on Tuesday they have begun delivering doses of their experimental coronavirus vaccines for initial human testing in the United States.
The U.S. drugmaker and German partner said if the vaccine proves to be safe and effective in trials, it could potentially be ready for wide U.S. distribution by the end of the year, shaving several years off the typical vaccine development timeline.
The vaccine, which uses messenger RNA (mRNA) technology, has the potential to be among the first vaccines against the virus that has infected more than 1 million people in the United States and killed some 68,000.
There are currently no approved treatments or vaccines for the new coronavirus, though some drugs are being used on patients under an emergency use authorization.
The U.S. study is part of a broader, global program already underway in Germany, where
You’ve reached your free article limit
Create a free account to unlock every article for 14 days. No card needed, and nothing is charged when the trial ends.
Start your 14-day free trialNeed help? molokom@insideeducation.co.za











